N/A
N=23
Continuous Glucose Monitoring in Diabetes and Prediabetes
Diabetes Mellitus, Type 2 · PreDiabetes · Obesity
Bottom Line
View on ClinicalTrials.gov: NCT03805412 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcome: Primary: Percent Change in BMI From Baseline to 14 Weeks — -0.3; -0.2 % change over 14 weeks
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- DEXCOM G6 RT-CGM (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Nicole Ehrhardt, MD
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in BMI From Baseline to 14 Weeks |
-0.3; -0.2 | — |
| PRIMARY Percent Body Fat Change at 14 Weeks |
1.7; -1.6 | — |
| SECONDARY Questionnaire: Experiences With Glucose Monitoring (CGM) Diabetes |
75.8 | — |
| SECONDARY Mean Glucose Change at 14 Weeks |
-0.3; 23.0 | — |
| SECONDARY Food Frequency Change in Score at 14 Weeks |
-2.0; 0 | — |
| SECONDARY Change in Minutes Walked Per Week at 14 Weeks |
438.8; 232.0 | — |
| SECONDARY MAGE Mean Amplitude of Glycemic Excursion |
95.1; 90.1 | 0.694 |
Summary
Evaluate the use of brief serial real time continuous monitoring (RT-CGM) as a behavior modification tool in obese patients with prediabetes and diabetes. After receiving RT-CGM, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . Education on how to interpret CGM in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.
Eligibility Criteria
Inclusion Criteria
- Age 18-55
- Prediabetes (A1c 6.0-6.4) or Diabetes (A1c 7.0-10)
- BMI ≥ 30 kg/m2
- Willing to wear pedometer during study period
- Able to walk 2 city blocks at baseline without assistance (self-reported)
- Reading level at least 6th grade in English
- Expected to remain in local community for at least 4 months
- Either is not treated with or has been on a stable treatment regimen of any of the following medications for a minimum of 3 months prior to Visit 1 (Screening/Enrollment):
- Sulfonylureas
- Biguanidine
- Thyroid replacement therapy
- Glp-1 agonists
- Sodium-glucose co-transporters
- Basal insulin
- Thiazolidinediones
- Hormone replacement therapy (female subjects) estrogen/progesterone products
- Oral contraceptives/birth control (female subjects)
- Antidepressant agents (SSRIs, Paxil, Prozac, Celexa, Zoloft, etc.)
- Is able to read, understand, and sign the Informed Consent Form (ICF) and if applicable, an Authorization to Use and Disclose Protected Health Information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.
Exclusion Criteria
- Women who are pregnant, lactating, planning to become pregnant
- Subjects who are taking amphetamines, anabolic, or weight-reducing agents
- Contraindications to moderate exercise
- Pre-prandial insulin
- On any antipsychotic medication or history of schizophrenia or bipolar disorder
- Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months
- Active wounds or recent surgery within 3 months
- Inflammatory disease, or chronic and current use of anti-inflammatory drugs or narcotics
- Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study
- Presence or history of severe congestive heart failure (New York Heart Association Class IV [CCNYHA 1994])
- Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant
- Enrolled in another weight loss program
- Already receiving continuous glucose monitoring (CGM)
Data sourced from ClinicalTrials.gov (NCT03805412). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.